InflaRx (IFRX) Competitors $0.92 +0.01 (+0.81%) Closing price 04:00 PM EasternExtended Trading$0.93 +0.01 (+1.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. TKNO, SCPH, ALLO, ANNX, PRQR, FENC, ALEC, SGMT, CRGX, and GNFTShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Annexon (ANNX), ProQR Therapeutics (PRQR), Adherex Technologies (FENC), Alector (ALEC), Sagimet Biosciences (SGMT), CARGO Therapeutics (CRGX), and GENFIT (GNFT). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors Alpha Teknova scPharmaceuticals Allogene Therapeutics Annexon ProQR Therapeutics Adherex Technologies Alector Sagimet Biosciences CARGO Therapeutics GENFIT InflaRx (NASDAQ:IFRX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Which has higher valuation & earnings, IFRX or TKNO? Alpha Teknova has higher revenue and earnings than InflaRx. Alpha Teknova is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$180K343.44-$49.85M-$0.80-1.15Alpha Teknova$37.74M6.35-$26.75M-$0.42-10.67 Do institutionals & insiders have more ownership in IFRX or TKNO? 42.4% of InflaRx shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 12.5% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is IFRX or TKNO more profitable? InflaRx has a net margin of 0.00% compared to Alpha Teknova's net margin of -55.24%. Alpha Teknova's return on equity of -26.51% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -71.76% -57.68% Alpha Teknova -55.24%-26.51%-18.40% Do analysts recommend IFRX or TKNO? InflaRx currently has a consensus price target of $6.60, suggesting a potential upside of 616.69%. Alpha Teknova has a consensus price target of $10.00, suggesting a potential upside of 123.21%. Given InflaRx's higher probable upside, equities analysts clearly believe InflaRx is more favorable than Alpha Teknova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility and risk, IFRX or TKNO? InflaRx has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Does the media prefer IFRX or TKNO? In the previous week, InflaRx had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for InflaRx and 0 mentions for Alpha Teknova. InflaRx's average media sentiment score of 0.00 equaled Alpha Teknova'saverage media sentiment score. Company Overall Sentiment InflaRx Neutral Alpha Teknova Neutral SummaryInflaRx beats Alpha Teknova on 9 of the 16 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.82M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.1520.9030.1925.84Price / Sales343.44387.71474.17122.81Price / CashN/A43.2325.7828.79Price / Book0.819.649.425.99Net Income-$49.85M-$54.08M$3.27B$265.29M7 Day Performance0.93%2.62%2.04%2.53%1 Month Performance2.47%4.05%3.58%0.92%1 Year Performance-41.72%9.48%30.08%18.70% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.646 of 5 stars$0.92+0.8%$6.60+616.7%-42.2%$61.82M$180K-1.1560Gap DownTKNOAlpha Teknova1.6521 of 5 stars$4.48+0.7%$10.00+123.2%-4.8%$238.14M$37.74M-10.67240SCPHscPharmaceuticals4.5245 of 5 stars$4.57+2.7%$14.00+206.3%-9.7%$237.18M$49.97M-2.5230News CoveragePositive NewsAnalyst ForecastGap UpTrading HaltedALLOAllogene Therapeutics2.6204 of 5 stars$1.12+5.7%$8.44+654.0%-54.4%$235.19M$20K-1.01310ANNXAnnexon2.9652 of 5 stars$2.17+1.4%$12.50+476.0%-60.8%$235.16MN/A-1.6860PRQRProQR Therapeutics2.8101 of 5 stars$2.21+3.3%$8.00+262.0%+5.6%$225.15M$20.46M-4.80180Positive NewsFENCAdherex Technologies1.9304 of 5 stars$8.17+1.1%$13.33+63.2%+51.9%$224.74M$33.30M-19.4510News CoverageAnalyst RevisionALECAlector3.8626 of 5 stars$2.27+3.2%$4.17+83.6%-52.5%$222.67M$100.56M-1.96270SGMTSagimet Biosciences2.8131 of 5 stars$7.35+2.4%$25.67+249.2%+141.8%$220.24M$2M-4.028CRGXCARGO Therapeutics2.165 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116Analyst UpgradeGNFTGENFIT2.1236 of 5 stars$4.25-1.6%$9.00+111.8%-0.8%$216.01M$76.77M0.00120Positive NewsGap Up Related Companies and Tools Related Companies Alpha Teknova Competitors scPharmaceuticals Competitors Allogene Therapeutics Competitors Annexon Competitors ProQR Therapeutics Competitors Adherex Technologies Competitors Alector Competitors Sagimet Biosciences Competitors CARGO Therapeutics Competitors GENFIT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access